Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • SamCurt
    Member
    • May 2010
    • 40

    #1

    Rebasing gene lengths when combining the FPKMs of several studies

    We're planning to combine FPKMs of several GEO datasets for our project. However, these projects uses different gene annotations on GRCh37--some use hg37 and some use hg19--for their gene counting.

    Do you think, in such a case, that it is necessary do "rebase" the FPKMs using gene lengths from the same annotation?
  • Brian Bushnell
    Super Moderator
    • Jan 2014
    • 2709

    #2
    I'd suggest regenerating the FPKMs from the raw data with a uniform pipeline, as the processing methodologies obviously differ, which can have an unexpectedly large effect on results.

    Comment

    • SamCurt
      Member
      • May 2010
      • 40

      #3
      Originally posted by Brian Bushnell View Post
      I'd suggest regenerating the FPKMs from the raw data with a uniform pipeline, as the processing methodologies obviously differ, which can have an unexpectedly large effect on results.
      The biggest problem is some of the data used has non-public SAM/BAMs, so I have to live with count-level data. This is not to mention some of these sets use Ensembl IDs, some use EntrezGene IDs and some use symbols...
      Last edited by SamCurt; 01-03-2017, 12:36 PM.

      Comment

      • Brian Bushnell
        Super Moderator
        • Jan 2014
        • 2709

        #4
        Personally, I am not very interested in unexplainable or unreproducible data. I think that reproducibility is essential to science; using black-box software or secret data is not explainable or reproducible, and thus not scientific, in my opinion. I suggest that you pursue something that is reproducible.

        Comment

        • WhatsOEver
          Senior Member
          • Apr 2012
          • 215

          #5
          In addition to what Brian wrote: Currently, >50% of the public data I'd like to use for comparison to my data are not reproducible with the published analyses pipelines. This is either because there are different 1-man-1-time-0-comments-custom-scripts that simply do not work or because essential information (e.g. program parameters!) are not provided anywhere. However, I can not simply ignore this existing data as it is sometimes also the only fitting reference in terms of sample prep, sequencing, etc...

          Hence, I currently take the most annoying and time consuming ways: Start at fastq, contact the authors, dig into the code. If the data is published in a peer-reviewed journal, you should be able to get access to the raw data, so you are able to reproduce the published results.

          Comment

          • SamCurt
            Member
            • May 2010
            • 40

            #6
            The complete code for one of those sets--the one I mentioned to currently only have "open" counts data" is available open source (I already saw the code). I just want to know how many days would I need to re-align those, since SRX toolkit is slow in my institution for some reason...

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
              by SEQadmin2




              NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
              Today, 06:46 AM
            • SEQadmin2
              Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
              by SEQadmin2



              Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

              Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
              ...
              10-14-2026, 09:55 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, 10-28-2026, 09:57 AM
            0 responses
            24 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 10-28-2026, 09:51 AM
            0 responses
            15 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 10-22-2026, 11:13 AM
            0 responses
            68 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 10-22-2026, 10:48 AM
            0 responses
            48 views
            0 reactions
            Last Post SEQadmin2  
            Working...